Healthcare DIVE January 31, 2023
Rebecca Pifer

Dive Brief:

  • Drugmakers are allowed to restrict providers’ use of community and specialty pharmacies to dispense drugs in the 340B drug discount program, a federal appeals court ruled Monday.
  • The decision is a win for drug manufacturers Sanofi, Novo Nordisk and AstraZeneca. The companies sued the HHS after regulators ordered them to stop restricting sales of 340B drugs to contract pharmacies.
  • The three-judge panel’s decision reverses a previous ruling in New Jersey against Novo Nordisk and Sanofi, and upholds one from Delaware in favor of AstraZeneca. It’s the first decision of three federal appeals courts considering multiple lawsuits over the pharmaceutical company’s 340B restrictions.

Dive Insight:

Providers and drug manufacturers have been at odds for years over the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, HHS, Pharma, Pharma / Biotech
Related Articles:
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
Key Trends in the Evolution of PBMs and Their Future Impact on Drug Pricing and Pharmacy Operations

Share This Article